Since their inception in 2016, LUNGevity Foundation’s Scientific and Clinical Roundtables (SCRTs) have leveraged its unique structure and multi-stakeholder participants to focus on defining and then achieving ideal patient-centric and efficient clinical trial and therapy development paradigms for lung cancer.

Remote Informed Consent

Using remote informed consent for clinical trial participants could make it easier for patients to enroll in trials. LUNGevity and the National Brain Tumor Society examined remote consent practices at major academic medical centers. Read their findings »

Illustration showing the desired characteristics of remote informed consent

Given the rapidly evolving therapeutic and diagnostic options in lung cancer, clinical trials are often the best treatment choices for patients with lung cancer today. Because of this, it is essential that patients have access to clinical trials and the ability to participate in them.

LUNGevity defines the ideal clinical trial paradigm as inclusive of most patients (mirroring the real world), conducted where patients are, reflective of what patients want and need, efficient, and incorporating risks in an appropriate manner.

To achieve the ideal clinical trial paradigm, LUNGevity's SCRTs convene global regulators, high-level research experts, clinical leads, industry sponsors, CROs, patient advocacy organizations, patients, and government agencies to identify and prioritize opportunities to streamline clinical trials and make them more patient-centric.

SCRTs have multiple workstreams and working groups focused on actionable areas across the entire clinical trial life cycle and are focused on goals such as advancing recommendations to expand eligibility criteria for lung cancer trials, reducing unnecessary and burdensome adverse event reporting, eliminating outdated exclusion criteria, identifying opportunities to leverage prospective synthetic controls, and improving patient-reported outcomes efforts and utility, among others. New workstreams are added as appropriate to tackle the most pressing issues in making clinical trials more patient-centric.

How clinical trials are conducted

Publications

 

If you are interested in learning more about or partnering with LUNGevity on Scientific and Clinical Roundtables, please reach out to Elizabeth Barksdale, Director of Regulatory Affairs and Scientific Policy, at ebarksdale@LUNGevity.org.